Jean-Pierre Sommadossi - 31 Jan 2025 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
President, CEO, and Chairman, Director
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Issuer symbol
AVIR
Transactions as of
31 Jan 2025
Net transactions value
-$271,119
Form type
4
Filing time
04 Feb 2025, 18:00:09 UTC
Previous filing
19 Sep 2024
Next filing
03 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +173,467 +149% 290,024 31 Jan 2025 Direct F1
transaction AVIR Common Stock Award +99,517 +34% 389,541 31 Jan 2025 Direct F2
transaction AVIR Common Stock Tax liability $271,119 -88,601 -23% $3.06 300,940 31 Jan 2025 Direct
holding AVIR Common Stock 5,866,025 31 Jan 2025 Held by JPM Partners LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -173,467 -50% $0.000000 173,466 31 Jan 2025 Common Stock 173,467 Direct F1, F3
transaction AVIR Restricted Stock Units Award $0 +99,518 $0.000000 99,518 31 Jan 2025 Common Stock 99,518 Direct F1, F4
transaction AVIR Stock Option (Right to Buy) Award $0 +440,000 $0.000000 440,000 31 Jan 2025 Common Stock 440,000 $3.06 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").
F3 The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F4 Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.
F5 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.